Home › Trial NCT05249959
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
- Trial IDNCT05249959
- StatusActive Not Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorFondazione Italiana Linfomi - ETS
- Enrollment49
- Start date2022-03-21
- ConditionsRelapsed Mantle Cell Lymphoma · Refractory Mantle Cell Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.